Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.